[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Udine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,43,70,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100547956","salivary-microrna-in-endometriosis-correlation-with-response-to-progestin-therapy-100547956",false,"NCT06414720","Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy","Salivary MicroRNA in Endometriosis: Correlation With Progestin Treatment Response: A Prospective Observational Study","ENDOmiRNA","INCLUSION CRITERIA\n\n* Age \\> 18 years\n* Fertile age\n* Clinical-ultrasound diagnosis or histological diagnosis of endometriosis\n* Informed consent\n\nEXCLUSION CRITERIA\n\n* Pregnancy\n* Pre-menarcheal or post-menopausal status\n* Chronic pelvic pain syndrome with or without central sensitization assessed with the Central Sensitization Inventory Test (CSI)\n* Neoplasia, diabetes, BMI \\> 30 kg\u002Fm2, coagulopathies, autoimmune diseases, or other conditions that may affect salivary miRNA measurement\n* Currently undergoing progestin therapy","FEMALE","18 Years","45 Years",{"count":21,"type":22},90,"ESTIMATED","OBSERVATIONAL","This study aims to analyze the salivary miRNA specific for patients diagnosed with endometriosis, specifically evaluating the miRNA profile of patients who respond versus those who do not respond to progestin therapy. Ninety patients attending the Chronic Pelvic Pain Clinic will be recruited, and they will be asked to provide a saliva sample before starting medical therapy. The response to the therapy will be evaluated after 4 months from the beginning of the therapy itself.",[26],"Endometriosis",[26,28,29],"miRNA","Progesterone resistance","RECRUITING","2025-03-27",{"date":33,"type":34},"2025-04-02","ACTUAL",{"date":36,"type":34},"2024-04-22",{"date":38,"type":22},"2025-12-01",{"name":40,"class":41},"University of Udine","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100585207","evaluation-of-clinical-progression-prognostic-factors-and-quality-of-life-in-patients-with-age-related-macular-degeneration-100585207","NCT06899360","Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration.","Evaluation of Clinical Progression, Prognostic Factors, and Quality of Life in Patients with Age-related Macular Degeneration (VERA-nAMD).","VERA-AMD","Inclusion Criteria:\n\n* age ≥ 50 years.\n* confirmed diagnosis of AMD in at least one eye.\n* follow-up scheduled according to standard clinical practice.\n\nExclusion Criteria:\n\n* presence of other significant ocular conditions that could affect visual acuity.\n* systemic conditions that make the patient unsuitable for long-term follow-up.","ALL","50 Years","120 Years",{"count":55,"type":22},200,"The VERA-AMD study is a prospective, observational study designed to evaluate clinical progression, prognostic factors, and quality of life in patients with age-related macular degeneration (AMD). The study aims to analyze real-world clinical data to identify key predictors of disease progression and functional outcomes, with the goal of optimizing AMD management. The study involves 200 patients aged ≥50 with a confirmed diagnosis of AMD, monitored through routine clinical practice. Primary outcomes include progression rates to advanced AMD and changes in visual acuity, while secondary outcomes focus on retinal morphology and quality of life. Anti-VEGF therapy and AI-based fluid analysis will be integrated to explore their impact on disease progression and patient outcomes.",[58],"Age-Related Macular Degeneration",[60,61,62],"age-related macular degeneration","artificial intelligence","anti-VEGF","2025-03-20",{"date":31,"type":34},{"date":66,"type":34},"2024-10-01",{"date":68,"type":22},"2029-10-01",{"name":40,"class":41},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":78,"enrollmentInfo":79,"targetDuration":81,"studyType":23,"phases":4,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100537008","tumor-microenvironment-in-ovarian-cancer-100537008","NCT06272240","Tumor Microenvironment in Ovarian Cancer","Study of the Role of the Tumor Microenvironment in Ovarian Cancer","MICO","Inclusion Criteria:\n\n* Age \\> 18 years\n* Age \\\u003C 80 years\n* Serous ovarian carcinoma\n* FIGO Stage III-IV\n\nExclusion Criteria:\n\n* Ongoing or suspended immunosuppressive therapy within the last 6 months\n* Congenital or acquired immunodeficiency\n* Immunosuppressive state\n* Administration of chemotherapy for another neoplasm in the past 12 months\n* Non-epithelial ovarian tumors\n* Patients not undergoing surgical intervention\n* BMI \\> 30\n* Absence of Informed Consent","80 Years",{"count":80,"type":22},50,"36 Months","A detailed understanding of molecular mechanism of cancer genesis is fundamental to develop innovative and personalized therapies. The new frontier in biomedical research is represented by organoids, a three-dimensional cell culture system obtained from a tissue fragment that accurately reproduces the essential properties of the original tissue in vitro, which could provide a valuable model for explanation of ovarian cancers pathogenesis and will allow to predict the response to a specific therapy. With this research project, we expect to generate ovarian cancer organoids to characterize in vitro interactions and molecular pathway among tumor cells, immune cells, and resident microbiota (intratumoral bacteria and\u002For microbial-derived molecules).",[84,85],"Ovarian Cancer Stage III","Ovarian Cancer Stage IV",[87],"organoids,tumor microenviroment,ovarian cancer","2024-02-14",{"date":90,"type":34},"2024-02-22",{"date":92,"type":34},"2024-01-02",{"date":94,"type":22},"2027-01",{"name":40,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":42},"100530462","the-supplementation-therapy-in-autism-and-response-to-treatment-study-100530462","NCT06187090","The Supplementation Therapy in Autism and Response to Treatment Study","The Supplementation Therapy in Autism and Response to Treatment (START) Study","START","Inclusion Criteria:\n\n* Individuals diagnosed with Level 1 ASD, as defined using Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5);\n* Aged 18-35 years;\n* To be able to understand and communicate in Italian;\n* To be able to give informed consent.\n\nExclusion Criteria:\n\n* Level 2 or Level 3 ASD, as defined using Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) \\[47\\];\n* Current diagnosis of a co-occurring major psychiatric disorder (e.g., major depressive disorder, bipolar affective disorder, psychotic disorders);\n* Active suicidal ideation indicating significant current risk or history of serious suicide attempt in the opinion of the PI, as evaluated at the screening stage;\n* Lifetime neurological disorders (e.g., epilepsy, except febrile convulsions) or severe intercurrent physical illness;\n* Current treatment with psychotropic medication, with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) stable monotherapy (at least 8 months);\n* IQ \\\u003C 70;\n* Female patients who are pregnant, lactating or not using an acceptable effective form contraception if they are at risk of falling pregnant;\n* Taking part in another pharmacological trial.","35 Years",{"count":106,"type":22},20,"INTERVENTIONAL",[109],"NA","In addition to the \"core\" symptoms of ASD (i.e., impaired communication, impaired reciprocal social interaction and restricted, repetitive and stereotyped patterns of behaviors or interests), it is estimated that up to 70% of autistic people present at least one comorbid psychiatric disorder, leading to a deterioration in quality of life, a greater demand for support and worse prognosis and outcome. Anxiety and depressive symptoms would seem to be more present in individuals with Level 1 ASD, requiring their prioritisation against core symptoms. To date, the first-line treatment for autistic patients with comorbid depressive and\u002For anxiety symptoms is still debated and it is not always clear whether they may or may not benefit from psychotherapeutic and conventional psychopharmacological approaches. As such, growing evidence strengthens the therapeutic potential of the endocannabinoid (eCB) system modulation and of eCB-like compounds.\n\nThe aim of this study is to provide a response to an unmet clinical need in this framework of psychic vulnerability by initiating oral therapy with palmitoylethanolamide (PEA), a nutraceutical\u002Ffood supplement with proven anti-inflammatory and neuroprotective properties.\n\nIndeed, many conditions of psychological distress are thought to be underpinned by systemic inflammatory and\u002For neuroinflammatory processes, on which PEA has shown remarkable efficacy, including through modulation of the immune response and the interaction between the endocannabinoid system and the gut-microbiota-brain axis.\n\nThe trial we are proposing is a 12-week open-label phase 2 study involving the daily intake of PEA 600 mg, at a dosage of 1 tablet\u002Fday.\n\nThis study will be conducted at the Unit of Psychiatry of Santa Maria della Misericordia Udine University Hospital.\n\nThrough this study, we wish to evaluate: the ability of PEA to alleviate symptoms of psychic distress (i.e., anxiety and\u002For depression) in Level 1 autistic adults; the safety and tolerability of sustained intake of PEA in Level 1 autistic adults; and the biological basis of PEA functioning.\n\nThe study involves taking PEA orally once daily (600 mg daily) at the same time as a meal during the initial 12-week phase. Upon completion of the initial phase, subjects will be offered to enter an extension phase of the trial of an additional 24 weeks to assess treatment stability, with the possibility of titration of PEA to 1200 mg daily based on observed clinical compensation. Each participant will be on PEA treatment for up to 36 weeks.\n\nDuring the course of the study, periodic clinical re-evaluations will be conducted at our Day-Hospital setting.\n\nThe trial will unfold through one screening visit, one baseline visit, and two follow-up visits (FUP, 4 weeks and 12 weeks apart). The patient will be administered standardized interviews by a qualified investigating physician; clinical objective examination, collection of blood and urine samples for standard hematochemical investigations, collection of blood and stool samples for analysis of some biological markers of interest, monitoring of adherence to therapy intake, side effects, and adverse effects will also be performed during the follow-up visits. The nutraceutical PEA will be dispensed by the clinical investigators at each follow-up visit.",[112,113,114,115,116,117],"Autism","Autism Spectrum Disorder","Autism Spectrum Disorder High-Functioning","Asperger Syndrome","Depressive Symptoms","Anxiety State","2023-12-15",{"date":92,"type":34},{"date":121,"type":34},"2023-09-01",{"date":123,"type":22},"2026-11",{"name":40,"class":41},""]